Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2001-04-05
2004-08-17
Meller, Michael (Department: 1654)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C435S206000, C424S043000
Reexamination Certificate
active
06776989
ABSTRACT:
BACKGROUND OF THE INVENTION
Lysozyme is increased in inflammatory reactions and is a component of the extracellular matrix, but its possible role in lung diseases such as emphysema and interstitial fibrosis has not been investigated. Determining the significance of any changes in pulmonary lysozyme content is complicated by the fact that this protein has no recognized physiological function in the lung other than protecting it from bacterial infection (
1
-
3
).
To further understand the role of lysozyme in pulmonary disease, tissue sections from normal, fibrotic, and emphysematous human lungs were evaluated for differences in lysozyme content. An increase in extracellular lysozyme was specifically observed in lung tissues with pulmonary emphysema, and the protein was preferentially associated with elastic fibers, which undergo breakdown in this disease (
4
).
Since this laboratory and other investigators have previously shown that hyaluronan and other polysaccharides surround elastic fibers (
5
-
7
), normal lung tissues were treated with hyaluronidase and examined for their ability to bind exogenously administered lysozyme. Such treatment resulted in increased attachment of lysozyme (
4
), suggesting that degradation of extracellular matrix components, as occurs in pulmonary emphysema, may expose binding sites for lysozyme on elastic fibers. In vitro studies, using an extracellular matrix preparation mainly composed of elastic fibers, confirmed that lysozyme has a strong affinity for these fibers (unpublished observations).
While the mechanism responsible for the observed affinity of lysozyme for elastic fibers is unclear, it is possible that lysozyme may bind to specific carbohydrate residues in elastic fibers. N-acetyl-D-glucosamine, a component of bacterial cells susceptible to degradation by lysozyme, has also been found in glycoproteins associated with elastic fibers (
8
). Injury to elastic fibers, as occurs in pulmonary emphysema, may expose such residues, thereby facilitating lysozyme binding.
The enhanced binding of lysozyme to elastic fibers in pulmonary emphysema may protect these fibers from further injury. Previous work by other investigators has shown that lysozyme prevents elastolysis in vitro (
9
). Lysozyme could therefore be useful in treating emphysema and other diseases involving damage to elastic fibers, such as asthma, pulmonary fibrosis, respiratory distress syndrome, bronchopulmonary dysplasia, and cystic fibrosis. This protective effect of lysozyme would complement its antibacterial properties (
1
-
3
) and make it particularly beneficial in the treatment of certain types of pulmonary infections where there is necrotizing lung injury. Similarly, lysozyme has been reported to counteract HIV infection (
10
) and may therefore be useful in the treatment of pneumonias and other disorders associated with AIDS.
Another useful property of lysozyme is its ability to bind to and disaggregate hyaluronan and other polyanionic compounds (
11
). Lysozyme might therefore be utilized to treat lung diseases involving excess mucus secretion in airways. In particular, this protein may help alleviate the obstruction of airways associated with pneumonias, asthma, and cystic fibrosis.
This same ability of lysozyme to disaggregate hyaluronan may also be beneficial in pulmonary fibrosis, where significant accumulation of this polysaccharide occurs in conjunction with collagen, elastin and other polysaccharides (
12
-
14
). By disaggregating hyaluronan, lysozyme may interfere with the fibrotic process, thereby ameliorating the disease. As shown in studies from this laboratory (
4
), there is a decrease in lung lysozyme content in pulmonary fibrosis (relative to the proliferation of other tissue components), which may conceivably facilitate the fibrotic response.
With regard to intratracheal administration of lysozyme, this laboratory has shown that an aerosol preparation of the protein rapidly penetrates the lung, remains there for at least 24 hrs, and does not cause pulmonary injury (unpublished observations). These findings suggest that lysozyme could also act as a vehicle for intratracheal delivery of drugs for the treatment of pulmonary and systemic diseases. By virtue of its attachment to elastic fibers, lysozyme could slow the pulmonary clearance of inhaled therapeutic agents, thereby increasing their effectiveness in the lung.
SUMMARY OF THE INVENTION
The subject invention is directed to the treatment of respiratory disorders by intratracheal administration of an effective amount of lysozyme. Respiratory disorders include emphysema, pneumonia, respiratory distress syndrome, bronchopulmonary dysplasia, interstitial fibrosis, cystic fibrosis, and neoplasia. The treatment is intended for a variety of mammals, such as premature neonates to adult humans.
Administration of lysozyme may be performed by aerosol, which can be generated by a nebulizer, or by instillation. The lysozyme may be administered alone, or with a carrier such as saline solution, DMSO, an alcohol, or water. It may also be used as a vehicle for the intratracheal administration of drugs or other agents to the lung. The lysozyme may be isolated from a natural source, such as eggs, or synthesized by a bioprocess, such as fermentation. The effective daily amount of lysozyme is from about 10 &mgr;g/kg to about 1 mg/kg of body weight.
REFERENCES:
patent: 5993809 (1999-11-01), Weaver et al.
Luniakin et al., Pediatriia, Akusherstvo, I Ginekolgiia, Jan.-Feb. 1977 (1), 11-13. “Lysozyme in the overall treatment of children with influenza infection and pneumonia”.*
Vyrenkov et al., Antibiotiki, 1982, 27(6), 440-447.*
Gavrilenko et al. The Characteristics of lysozyme and carbenicillin action on the clinico-immunological status of patients with chronic bronchitis. Lik Sprava, 1992, Aug;(8):42-45, abstract.
Kats et al. Prevention and treatment of early post-intubation complications using lysozyme. Anesteziol Reanimatol, 1986, May-Jun.; (3):61-2, abstract.
Zhorov et al. Prevention of early post-intubation complications. Eksp Khir Anesteziol, 1971, Jan.-Feb.; 16(1):58-62, abstract.
Cantor Jerome Owen
Shteyngart Bronislava
LandOfFree
Intratracheal administration of lysozyme does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Intratracheal administration of lysozyme, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Intratracheal administration of lysozyme will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3286909